Clinical benefits and cost reduction associated with a comprehensive asthma management programme at a managed care organisation

Disease Management and Health Outcomes

Volumn 4, Issue 2, 1998, Pages 93-100

  Groban, Mark D ^b   Evans, Raeburn M ^b   Edgren, Bruce ^b   Butt, Linda T ^b   De Stefano, Alicia ^b   Fernandes, Douglas J ^b   Buchner, Deborah A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; STEROID;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE;

EID: 0031726772     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199804020-00003     Document Type: Article

References (3)

1. Lansky D. FACCT Memoradum. Portland (OR): Foundation for Accountability, Inc. 1997 May 16
2. Epstein RS, Sherwood LS. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med 1996; 124: 832-7
3. National Asthma Education and Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma [publication no.97-405]. Bethesda (MD): National Institutes of Health, NHLBI, 1997